Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alzamend Neuro, Inc. (ALZN : NSDQ)

• Company Description    Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $3.05 Daily Weekly Monthly 20 Day Moving Average: 225,119 shares Shares Outstanding: 0.80 (millions) Market Capitalization: $2.44 (millions) Beta: -0.31 52 Week High: $63.27 52 Week Low: $2.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.39% -7.97% 12 Week -49.42% -57.46% Year To Date -70.79% -72.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3480 Peachtree Road NE Second Floor Suite 103 - Atlanta,GA 30326 USA ph: 844-722-6333 fax: - None http://www.alzamend.com

• General Corporate Information    Officers Stephan Jackman - Chief Executive Officer and Director William B. Horne - Chairman of the Board David J. Katzoff - Chief Financial Officer Henry Nisser - Executive Vice President; General Counsel and Dire Kenneth S. Cragun - Senior Vice President of Finance Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 02262M605 SIC: 2834 Fiscal Year Fiscal Year End: April Last Reported Quarter: 01/01/25 Next Expected EPS Date: 07/29/25 Share - Related Items Shares Outstanding: 0.80 Most Recent Split Date: 5.00 (0.11:1) Beta: -0.31 Market Capitalization: $2.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-15.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/29/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 95.00% vs. Previous Quarter: 52.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/25 - - 01/31/25 - -497.73 10/31/24 - - ROA 04/30/25 - - 01/31/25 - -147.21 10/31/24 - -289.14 Current Ratio 04/30/25 - - 01/31/25 - 5.44 10/31/24 - 3.80 Quick Ratio 04/30/25 - - 01/31/25 - 5.44 10/31/24 - 3.80 Operating Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Net Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Pre-Tax Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Book Value 04/30/25 - - 01/31/25 - 5.72 10/31/24 - 6.46 Inventory Turnover 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - - 01/31/25 - 0.00 10/31/24 - 0.00 Debt-to-Capital 04/30/25 - - 01/31/25 - 0.00 10/31/24 - 0.00

Powered by Zacks Investment Research ©